How do healthcare providers enable positive outcomes for their pediatric patients while also addressing the disparities in care between patients of different ethnicities, gender and socioeconomic backgrounds? Experts addressed how changes in research and clinical care can improve outcomes for children experiencing healthcare disparities during a session at the 2023 Pediatric Rheumatology Symposium.
Artificial intelligence, social media, mobile apps—different technologies can be used to connect with and benefit rheumatology patients. During a session of the 2023 Pediatric Rheumatology Symposium, Dr. Jonathan Hausmann discussed the use of technology in research to improve patient recruitment and engagement, collect data and more.
The ACR Education Exchange 2023 session titled Updates from the Committee on Rheumatology Training & Workforce Issues provided information on fellows-in-training scholarships, Rheumatology Research Foundation awards & more.
Speakers addressed major challenges in coverage and payment facing rheumatology practices, including financial management and obstacles to patient access to treatment.
Disparities, representativeness, algorithmic bias, the disruptive emergence of large language models and continued misinformation spread are key issues poised to transform patient care in American healthcare, FDA Commissioner Robert M. Califf, MD, said during a recent event.
Patient advocates, researcher-clinicians and academic leaders are calling for closer scrutiny of new technologies applied within healthcare, citing concerns about a lack of consideration for how they may affect patient care.
ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.
Ho et al. found that upadacitinib may impede the progression of bone erosion in patients with RA. Additionally, bone scans of patients with limited exposure to conventional synthetic disease-modifying antirheumatic drugs showed bone erosion regression, which may result from upadacitinib’s inhibition of Janus kinase 1.
Stimulating human programmed cell death protein 1 (PD-1), a checkpoint inhibitory receptor, with peresolimab may be a viable way to treat autoimmune diseases, according to a study by Tuttle et al. In the study, patients with active rheumatoid arthritis (RA) who were treated with peresolimab experienced greater improvements in disease activity than those who received placebo.
An in-person poster hall and networking lounges are among the highlights attendees can expect at ACR Convergence 2023 in San Diego, Nov. 10–15.